Advertisement
Research Article

A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor Receptor

  • Aislyn D. W. Boran,

    Affiliation: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

    X
  • Joseph Seco,

    Affiliation: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

    X
  • Vinodh Jayaraman,

    Affiliation: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

    X
  • Gomathi Jayaraman,

    Affiliation: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

    X
  • Shan Zhao,

    Affiliation: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

    X
  • Sushmitha Reddy,

    Affiliation: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

    X
  • Yibang Chen,

    Affiliation: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

    X
  • Ravi Iyengar mail

    ravi.iyengar@mssm.edu

    Affiliation: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

    X
  • Published: November 15, 2012
  • DOI: 10.1371/journal.pone.0049702

About the Authors

Aislyn D. W. Boran, Joseph Seco, Vinodh Jayaraman, Gomathi Jayaraman, Shan Zhao, Sushmitha Reddy, Yibang Chen, Ravi Iyengar
Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Corresponding Author

Email: ravi.iyengar@mssm.edu

Competing Interests

The authors have read the journal’s policy and have the following conflicts: U.S. Patent Application: AB, YC and RI “Cell-permeable peptides as receptor tyrosine kinase antagonists.” U.S. Patent Application no. 61/107,650. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: AB YC RI. Performed the experiments: AB JS VJ GJ SR YC. Analyzed the data: AB JS VG SZ. Wrote the paper: AB RI.